Sintonen H, Lonnqvist J; International Society of Technology Assessment in Health Care. Meeting.
Abstr Int Soc Technol Assess Health Care Meet. 1993; 9: 222.
University of Kuopio, Finland.
BACKGROUND. In recent years many new drugs have been introduced for the treatment of depression. This raises the question whether there are differences between drug regimens in cost-effectiveness. Recently a prospective double-blind RCT was finished in Finland, where clinical efficacy, quality of life, and costs of fluoxetine and moclobemide regimens are compared in the treatment of depression. Obviously this is the most extensive study of this kind carried out so far in the field of psychiatry. METHODS. The study is based on a prospective, double-blind, multicenter RCT. In all 209 depressed patients entering outpatient clinics or psychiatric hospitals (30 centers) were assigned randomly to the regimens. The treatment period was 6 weeks. Quality of life was assessed at 0, 2 and 6 weeks by using 15D and MOS. 15D is a 15-dimensional measure of health-related quality of life with a two-stage valuation method to convert the different 15-dimensional states into a single score ranging from 1 to 0. RESULTS. The data collection was just finished and the code opened, but at this stage no results are yet available. The purpose is to present at the conference results regarding the impact on the regimens on the quality of life of the patients. The regimens will be compared in the light of the 15D-results and MOS-results over the treatment period. A comparison will also be made how the results based on the quality of life measures relate to the results based on some clinical depression measures.
Publication Types:
Keywords:
- Depression
- Depressive Disorder
- Double-Blind Method
- Finland
- Fluoxetine
- Humans
- Life
- Longitudinal Studies
- Moclobemide
- Pharmaceutical Preparations
- Placebos
- Quality of Life
- therapy
- hsrmtgs
Other ID:
UI: 102211602
From Meeting Abstracts